We are pleased to release the results of the fiscal year 2015, with a Net Profit of 4.8 € million, that represent a growth of 21.1% compared to the previous year 2014.
Revenues of the Company reached 85.5 € million, +3.5% growth while in Q42015 growth reached +5.6%.
At EBITDA level, we reached 11.3 € million, a +7.1% growth compared to the previous year. In Q42015, growth reached double digit, up to + 22.7%.
Regarding our Dividend Policy, we are also delighted to report a dividend distribution of 3.6 € million in 2015 (0.22 € per share), which represent a dividend yield of 4.1% taking into consideration the price of the stock as of December 31st 2015, and a Pay – Out ratio of 80%.
Net Debt improved reaching 1.3 € million (3.1 € million as of 31st December 2014). Looking ahead, the Company remains focused on growth and consolidation of our position Looking ahead, the Company remains focused on growth and consolidation of our position in the existing markets, the main drivers of which are: a) improvement of our market share;
b) opening of new clinics in Germany and Spain; c) market growth in emerging products..